Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (3341)	12/16/1997 12:05:00 PM
From: Henry Niman	Read Replies (3) of 6136

John, Jesse Eisinger is just agreeing with what I posted when initial PI data came out a few years ago. I indicated at that time that although the initial data looked very good, resistance would develop and the new resistant strains would make treatment harder than ever. I do read thestreet.com fairly regularly and was surprised to see the reported resistance with Viracept (although I expected resistance to develop to all of the PIs, I was under the impression that Viracept offered a unique advantage in that area, so I came to this board for more info). As far as resistance eventually causing an increase in KS, I posted that months ago on the LGND board. I think that anyone who clicks on my name can see where I do the bulk of my posting.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next